TrialESMO open2026

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

S-A Im et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.